Text Size

Effect of a L. Paracasei Strain on Grass Pollen Allergic Rhinitis Subjects

This study has been completed.
Sponsor:
Information provided by:
Nestlé
ClinicalTrials.gov Identifier:
NCT01233154
First received: November 2, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
  Purpose

Various studies in animal and humans have shown a potential beneficial effect of probiotics consumption on allergy. However few studies exist that document their efficacy for upper airways allergies such as allergic rhinitis. The objective of this study is to investigate the effect of short-term oral administration of a L. paracasei or of a blend of 2 probiotics (L. acidophilus + B. lactis) on a nasal provocation test (NPT) with grass pollen, performed out of the pollen season. Adult volunteers with allergic rhinitis are enrolled in a randomized, double-blind study, based on two 4-weeks cross-over periods of product consumption separated by a washout period of 6-8 weeks. Objective and subjective clinical parameters of NPT as well as systemic and nasal immunological markers are compared before and after each treatment.


Condition Intervention
Allergic Rhinitis
 Dietary Supplement: probiotic

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind

Further study details as provided by Nestlé:

Arms Assigned Interventions
Experimental: L. paracasei Dietary Supplement: probiotic
Experimental: L. acidophilus + B. lactis Dietary Supplement: probiotic

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • age 18-40 years old
  • history of allergic rhinitis during the latest grass pollen season confirmed by a positive skin prick test to grass pollen (wheal diameter > 3mm) and a positive response to a NPT with grass pollen (combined nasal reaction threshold <= 10000 standardized quality units/ml at the screening phase

Exclusion Criteria:

  • any medical condition that could influence the study (pregnancy, viral or bacterial airway infection, active allergic rhinitis)
  • uncontrolled asthma (peak expiratory flow <20% of volunteer's best personal value)
  • treatment with antihistamine or antibiotic treatment less than two weeks before enrolment or during the trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01233154

Locations
Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, 1011
Sponsors and Collaborators
Nestlé
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01233154     History of Changes
Other Study ID Numbers: 07.27.NRC
Study First Received: November 2, 2010
Last Updated: November 2, 2010
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on May 22, 2013